Craft

Vertex Pharmaceuticals

Stock Price

$492.1

2024-07-11

Market Capitalization

$127 B

2024-07-11

Revenue

$9.9 B

FY, 2023

Vertex Pharmaceuticals Summary

Company Summary

Overview
Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines. It is engaged in clinical development programs in cystic fibrosis and other conditions such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, duchenne muscular dystrophy, type 1 diabetes, and acute and chronic pain.
Type
Public
Status
Active
Founded
1989
HQ
Boston, MA, US | view all locations
Website
https://www.vrtx.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Reshma Kewalramani

    Reshma Kewalramani, Chief Executive Officer, President & Director

  • David Altshuler

    David Altshuler, Executive Vice President, Global Research and Chief Scientific Officer

  • Carmen Bozic

    Carmen Bozic, Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer

  • Stuart A. Arbuckle

    Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer

    Operating MetricsView all

    Products

    6

    FY, 2022

    Clinical Trials

    3

    FY, 2022

    LocationsView all

    23 locations detected

    • Boston, MA HQ

      United States

      50 Northern Ave

    • Providence, RI

      United States

      225A Carolina Avenue

    • San Diego, CA

      United States

      3215 Merryfield Row

    • Washington, DC

      United States

      1050 K St NW

    • St Leonards, NSW

      Australia

      level 3 suite 3/601 Pacific Hwy

    • Wien, Wien

      Austria

      Lehrbachgasse 13 EURO Plaza, Gebäude H

    and 17 others

    Vertex Pharmaceuticals Financials

    Summary Financials

    Revenue (Q1, 2024)
    $2.7B
    Gross profit (Q1, 2024)
    $2.3B
    Net income (Q1, 2024)
    $1.1B
    Cash (Q1, 2024)
    $9.2B
    EBIT (Q1, 2024)
    $1.1B
    Enterprise value
    $118.2B

    Footer menu